KRYS May 2024 230.000 call
| Previous close | 0.4000 |
| Open | 1.9400 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 230.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3100 - 1.9400 |
| Contract range | N/A |
| Volume | |
| Open interest | 448 |
GlobeNewswireKrystal Biotech to Present at the American Thoracic Society 2024 International Conference
PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic Society (ATS) 2024 International Conference being held from May 17-22, 2024 in San Diego, California. KB407 and KB408 are modified, replication-defective, non-integrating HSV-1 vectors formulated for in
- GlobeNewswire
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:20 pm PT and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at
Insider MonkeyKrystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call Transcript
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call Transcript May 6, 2024 Krystal Biotech, Inc. misses on earnings expectations. Reported EPS is $0.03182 EPS, expectations were $0.2. Krystal Biotech, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you […]
